Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination.

Antimicrobial Agents and Chemotherapy
G L DrusanoH C Standiford

Abstract

Because of the potential of novobiocin-rifampin for oral therapy of methicillin-resistant Staphylococcus aureus infection, we evaluated the pharmacokinetics of novobiocin and rifampin, alone and in combination, in a randomized, crossover, multiple-dose evaluation (500 mg of novobiocin and 300 mg of rifampin administered orally, twice a day, for 27 doses) in 10 volunteers. The half-lives of novobiocin and rifampin when administered alone were 5.85 +/- 1.20 and 1.46 +/- 0.30 h, respectively; when administered in combination, the half-lives were 2.66 +/- 0.65 and 1.43 +/- 0.29 h, respectively. This difference was significant for novobiocin. The area under the curve also differed significantly for novobiocin when administered in combination. No significant differences were seen in the maximum concentration of drug in serum, the time to maximum concentration of drug in serum, or both for either drug when single and combination therapy groups were compared. A change in clearance of novobiocin rather than a change in absorption is the more likely explanation for these findings. The mechanism remains to be elucidated. Nevertheless, the trough serum concentrations of both novobiocin and rifampin were in excess of the MIC for 90% of stra...Continue Reading

References

Mar 1, 1979·Computer Programs in Biomedicine·D Z D'Argenio, A Schumitzky
Apr 1, 1985·The Journal of Antimicrobial Chemotherapy·T J WalshH C Standiford
Oct 1, 1968·Gut·G AcocellaL T Tenconi
Jul 1, 1983·Reviews of Infectious Diseases·G Acocella
Aug 1, 1984·Archives of Internal Medicine·A M Baciewicz, T H Self
Dec 1, 1982·Annals of Internal Medicine·R L Thompson, R P Wenzel
Jul 1, 1956·A.M.A. Archives of Internal Medicine·W M KIRBYW D NOYES

❮ Previous
Next ❯

Citations

Nov 1, 1987·Diagnostic Microbiology and Infectious Disease·B L JohnstonM E Mulligan
Jul 1, 1989·Diagnostic Microbiology and Infectious Disease·R N Jones
Dec 10, 2013·Chemical Reviews·Claudine Mayer, Yves L Janin
Feb 3, 2000·Journal of the National Cancer Institute·M G MarcuL Neckers
Dec 1, 1993·Antimicrobial Agents and Chemotherapy·P FrenchH S Fraimow
Jul 29, 2003·Clinical Pharmacokinetics·Mikko NiemiKari T Kivistö
Nov 27, 2009·Diagnostic Microbiology and Infectious Disease·Violeta Rodríguez-CerratoFrancisco Soriano
Jan 7, 2009·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Koichi InoueHisao Oka
Mar 23, 2010·International Journal of Antimicrobial Agents·Violeta Rodríguez-CerratoFrancisco Soriano
Mar 31, 2016·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Lisa M AlmondJane R Kenny
May 18, 2006·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Matthew E FalagasIoannis A Bliziotis
Mar 29, 2011·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Yang XuGary L Skiles
Aug 2, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Magang ShouGary L Skiles

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.